Benchmark Reiterates Buy on Biofrontera, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Bruce Jackson has reiterated a 'Buy' rating on Biofrontera (NASDAQ:BFRI) and maintained a price target of $18.
August 31, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a 'Buy' rating on Biofrontera and maintained a price target of $18.
The reiteration of a 'Buy' rating by a Benchmark analyst and the maintenance of a price target of $18 indicates a positive outlook for Biofrontera. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100